Posted by Michael Wonder on 20 Jun 2023
CSL Behring announces the first patient has received FDA approved Hemgenix (etranacogene dezaparvovec-drlb) for haemophilia B
20 June 2023 - Hemgenix, the first and only FDA approved gene therapy for haemophilia B, has been proven to elevate and sustain factor IX levels for years, significantly reduce the rate of annual bleeds versus standard of care, and reduce or eliminate the need for prophylactic treatment in 94% of patients (51 out of 54) after a one-time infusion.
CSL Behring today announced that the first patient has received US FDA approved Hemgenix (etranacogene dezaparvovec-drlb) for haemophilia B in the United States.
